EGFR and prostate cancer: Pathway enrichment analysis using Enrichr22 revealed that the target genes of both miR-182 and miR221/222 are highly associated with a wide range of cancer types (Supplementary Fig. 3B and C), including endometrial cancer, ovarian cancer, pancreatic ductal cancer, breast cancer, prostate cancer, glioblastoma and hepatocellular carcinoma with the underlying molecular processes involving the FoxO and the ErbB pathways (Fig. 4A,B).